skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

FACE: the barefaced facts of AI potency

Review

(1656) Views  (387) Full article downloads

Authors: Alain Monnier

Published Date October 2010 Volume 2010:2 Pages 267 - 276
DOI: http://dx.doi.org/10.2147/CMAR.S13511

Alain Monnier
Institut Régional Fédératif du Cancer (IFRC), Centre Hospitalier Belfort-Montbéliard, Montbeliard Cedex, France

Abstract: The use of third-generation aromatase inhibitors (AIs), such as anastrozole and letrozole, as initial adjuvant hormonal therapy in postmenopausal women (PMW) with hormone receptor-positive (HR+) breast cancer offers a significant benefit over tamoxifen for reducing recurrence risk. Clinical studies, including the Arimidex Tamoxifen Alone or in Combination (ATAC) and the Breast International Group (BIG) 1-98 trials, have proven that both anastrozole and letrozole are, respectively, superior to tamoxifen in improving disease-free survival. Although differing in design, objectives, and follow-up time, these trials offer some insight into the comparative clinical efficacy of these two nonsteroidal AIs. In particular, results from BIG 1-98 show that letrozole significantly reduces early distant metastatic (DM) events, which constitute the majority of early recurrence events. Subsequently, there is a beneficial overall survival effect emerging in the trial, whereas survival is unchanged with anastrozole after 100 months of follow-up in ATAC. Significant differences in the potency of these two drugs, vis-à-vis their degree of aromatase inhibition, have been observed in comparative trials and show that letrozole causes a more complete suppression of estrogen levels than does anastrozole. Whether this difference in potency is relevant to reductions in DM events during adjuvant therapy remains unclear. The Femara Anastrozole Clinical Evaluation trial is addressing this issue in a more unequivocal manner by comparing initial adjuvant treatment with anastrozole or letrozole in a population of breast cancer patients at high risk of recurrence: PMW with HR+ disease and axillary lymph node involvement.

Keywords: anastrozole, aromatase inhibitors, hormone receptor-positive (HR+) breast cancer, letrozole, postmenopausal women, tamoxifen




 

Other articles by Dr Alain Monnier



Readers of this article also read:

Long-term safety of aromatase inhibitors in the treatment of breast cancer
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Aromatase inhibitor strategies in metastatic breast cancer
Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review
Ixabepilone development across the breast cancer continuum: a paradigm shift
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management
Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study
Review of catumaxomab in the treatment of malignant ascites
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University